利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

52 条记录 (耗时 0.045 秒)

    PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
    1.
    发明申请
    PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS 有权
    作为酪氨酸激酶抑制剂的吡唑并嘧啶衍生物

    公开(公告)号：US20140221398A1

    公开(公告)日：2014-08-07

    申请号：US14117927

    申请日：2012-05-16

    申请人： David Michael Goldstein ,  Kenneth Albert Brameld

    发明人： David Michael Goldstein ,  Kenneth Albert Brameld

    IPC分类号： C07D487/04

    CPC分类号： C07D487/04

    摘要： The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.

    摘要翻译： 本公开提供了酪氨酸激酶抑制剂，特别是BLK，BMX，EGFR，HER2，HER4，ITK，Jak3，TEC，Btk和TXK的化合物和药学上可接受的盐，因此可用于治疗可通过抑制 酪氨酸激酶如癌症和炎性疾病如关节炎等。 还提供了含有这些化合物的药物组合物和药学上可接受的盐以及制备这些化合物和药学上可接受的盐的方法。

    Tyrosine Kinase Inhibitors
    2.
    发明申请
    Tyrosine Kinase Inhibitors 有权
    酪氨酸激酶抑制剂

    公开(公告)号：US20140094459A1

    公开(公告)日：2014-04-03

    申请号：US14117933

    申请日：2012-05-16

    申请人： David Michael Goldstein ,  Kenneth Albert Brameld

    发明人： David Michael Goldstein ,  Kenneth Albert Brameld

    IPC分类号： C07D487/04 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/519

    CPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06

    摘要： The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

    摘要翻译： 本公开提供了酪氨酸激酶抑制剂，特别是BLK，BMX，EGFR，HER2，HER4，ITK，TEC，BTK和TXK的化合物及其药学上可接受的盐，因此可用于治疗通过抑制酪氨酸可治疗的疾病 激酶如癌症和炎性疾病如关节炎等。 还提供含有这些化合物及其药学上可接受的盐的药物组合物和制备这些化合物的方法及其药学上可接受的盐。

    Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
    3.
    发明授权
    Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors 有权
    吡唑并嘧啶衍生物作为酪氨酸激酶抑制剂

    公开(公告)号：US09376438B2

    公开(公告)日：2016-06-28

    申请号：US14117927

    申请日：2012-05-16

    申请人： David Michael Goldstein ,  Kenneth Albert Brameld

    发明人： David Michael Goldstein ,  Kenneth Albert Brameld

    IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61P29/00 ,  A61P19/02 ,  A61P11/06 ,  A61P17/06

    CPC分类号： C07D487/04

    摘要： The present disclosure provides compounds of Formula (I)and pharmaceutically acceptable salts that are tyrosine kinase inhibitors,in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.

    摘要翻译： 本公开提供式（I）化合物和其药学上可接受的盐，其是酪氨酸激酶抑制剂，特别是BLK，BMX，EGFR，HER2，HER4，ITK，Jak3，TEC，Btk和TXK，因此可用于治疗 通过抑制酪氨酸激酶如癌症和炎性疾病如关节炎等可治疗的疾病。 还提供了含有这些化合物的药物组合物和药学上可接受的盐以及制备这些化合物和药学上可接受的盐的方法。

    Tyrosine kinase inhibitors
    9.
    发明授权
    Tyrosine kinase inhibitors 有权

    公开(公告)号：US08962831B2

    公开(公告)日：2015-02-24

    申请号：US14117933

    申请日：2012-05-16

    申请人： David Michael Goldstein

    发明人： David Michael Goldstein

    IPC分类号： C07D487/00 ,  C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06

    CPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06

    摘要： The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.